New Delhi: Sun Pharmaceutical Industries on Friday reported a 26.2 per cent year-on-year rise in consolidated net profit for the fourth quarter of FY26, driven by strong growth in its India formulations business and continued momentum in innovative medicines.
The company also announced a final dividend of Rs 5 per share for FY26, taking the total dividend payout for the financial year to Rs 16 per share, including the interim dividend already paid earlier.
Net profit rises to Rs 2,714 crore
According to a regulatory filing, Sun Pharma posted a consolidated net profit of Rs 2,714.03 crore for the quarter ended March 31, 2026, compared to Rs 2,149.88 crore during the corresponding period last year.
The company’s revenue from operations also witnessed healthy growth during the quarter.
Total revenue stood at Rs 14,611.79 crore in Q4 FY26, up from Rs 12,958.84 crore reported in the same quarter of the previous financial year.
However, total expenses during the quarter also increased significantly to Rs 11,518.95 crore compared to Rs 9,955.68 crore a year earlier.
Company announces final dividend
Sun Pharma’s board recommended a final dividend of Rs 5 per equity share for FY26.
This comes in addition to the interim dividend of Rs 11 per share already paid during the financial year.
As a result, the total dividend payout for FY26 stands at Rs 16 per share, unchanged from FY25.
The announcement is expected to benefit shareholders as the company continues to maintain stable dividend distribution despite rising operational costs.
Full-year revenue crosses Rs 58,000 crore
For the full financial year FY26, Sun Pharma reported consolidated net profit of Rs 11,479.42 crore, compared to Rs 10,929.04 crore recorded in FY25.
The company’s total revenue from operations for FY26 rose to Rs 58,462.04 crore from Rs 52,578.44 crore in the previous fiscal year.
The strong performance was largely supported by growth in India formulations, innovative medicines and improving international operations.
India business records strong growth
Sun Pharma said its India formulations business delivered robust performance during the quarter.
India formulation sales stood at Rs 4,835.9 crore in Q4 FY26, registering a growth of 14.8 per cent year-on-year.
The domestic business contributed around 33.2 per cent of the company’s total consolidated sales during the quarter.
For the full financial year FY26, India formulation sales rose to Rs 19,290.4 crore, reflecting a 14 per cent increase compared to the previous year.
Managing Director Kirti Ganorkar said the company achieved its highest market share gain in India since the acquisition of Ranbaxy.
“Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition,” he said.
Innovative medicines business crosses major milestone
The company also highlighted strong performance in its innovative medicines portfolio.
Global innovative medicines sales reached USD 354 million during Q4 FY26, registering a growth of 20.1 per cent year-on-year.
This segment accounted for around 22.2 per cent of total sales during the quarter.
For the full financial year FY26, global innovative medicines sales stood at USD 1.42 billion, marking a 16.8 per cent increase compared to the previous fiscal year.
Ganorkar said the company’s US innovative medicines business had crossed the USD 1 billion revenue milestone.
“Our US innovative medicines business has surpassed USD 1 billion in revenues, while ex-US innovative medicines continue to demonstrate strong growth momentum,” he stated.
US formulations business sees slight decline
Sun Pharma’s US formulations business reported a marginal decline during the quarter.
US formulation sales stood at USD 459 million in Q4 FY26, down 1.1 per cent year-on-year.
The company said growth in innovative medicines helped offset weakness in the generics business.
The US market contributed nearly 28.8 per cent of Sun Pharma’s total consolidated sales during the quarter.
For the full financial year FY26, US formulations sales stood at USD 1.904 billion.
API business posts healthy quarterly growth
The company’s active pharmaceutical ingredients (API) business also reported positive growth during the quarter.
External API sales rose 26.4 per cent year-on-year to Rs 673.9 crore in Q4 FY26.
For the full financial year, API sales stood at Rs 2,185.3 crore, reflecting a growth of 2.6 per cent.
Organon acquisition to support future expansion
Sun Pharma also reiterated confidence in its recently announced acquisition involving Organon.
Ganorkar said the acquisition is expected to strengthen the company’s transformation into a leading global pharmaceutical player.
“The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company,” he added.
Industry analysts believe the acquisition could help Sun Pharma expand its global product portfolio and strengthen its presence in international markets.
Pharma sector continues growth momentum
The latest earnings reinforce the strong momentum currently being witnessed across India’s pharmaceutical sector, particularly in domestic formulations and specialty medicines.
Companies continue to benefit from rising healthcare demand, expanding chronic therapy markets and growing exports.
Sun Pharma remains one of India’s largest pharmaceutical firms with a significant presence across generics, specialty medicines and active pharmaceutical ingredients globally.